Inhibition of the enzyme activity of cytochrome P450 1A1, 1A2 and 3A4 by fucoxanthin, a marine carotenoid

Satomi,Yoshiko; Nishino,Hoyoku

doi:10.3892/ol.2013.1457

Inhibition of the enzyme activity of cytochrome P450 1A1, 1A2 and 3A4 by fucoxanthin, a marine carotenoid

Authors:
- Yoshiko Satomi
- Hoyoku Nishino
View Affiliations

Affiliations: Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513‑8670, Japan, Kyoto Prefectural University of Medicine, Kawaramachi‑Hirokoji, Kamigyo‑ku, Kyoto 602‑8566, Japan
Published online on: July 12, 2013 https://doi.org/10.3892/ol.2013.1457
Pages: 860-864

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fucoxanthin is a carotenoid that is mainly identified in brown algae and is known to have anticarcinogenic and anti‑tumor activities. Carotenoids have generally been shown to induce the expression and enzyme activity of the cytochrome P450s (CYPs). The present study evaluated the effect of fucoxanthin on the expression and enzymatic activity of the major xenobiotic metabolizing enzymes, CYP1A1, CYP1A2 and CYP3A4. Fucoxanthin markedly induced the expression of cyp1a1 mRNA in HepG2 cells, but inhibited its enzyme activity in the cells and in vitro. Fucoxanthin also inhibited the enzyme activity of CYP1A2 and CYP3A4 in a dose‑dependent manner in vitro. These results suggest that fucoxanthin may serve as a useful agent in cancer prevention with less adverse effects than β‑carotene, including the activation of pro‑carcinogens by CYPs.

View Figures

View References

1	Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA and Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 88:1550–1559. 1996. View Article : Google Scholar : PubMed/NCBI
2	Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ and Legator MS: Co-carcinogenic effect of beta-carotene. Nature. 398:760–761. 1999. View Article : Google Scholar : PubMed/NCBI
3	Guengerich FP: Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev. 36:159–197. 2004. View Article : Google Scholar
4	Nebert DW, Wikvall K and Miller WL: Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci. 368:201204312013. View Article : Google Scholar : PubMed/NCBI
5	Zhang JY, Wang Y and Prakash C: Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab. 7:939–948. 2006. View Article : Google Scholar : PubMed/NCBI
6	Shimada T: Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet. 21:257–276. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shimada T and Fujii-Kuriyama Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 95:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ma Q and Lu AY: CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos. 35:1009–1016. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kamdem LK, Meineke I, Gödtel-Armbrust U, Brokmöller J and Wojnowski L: Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res of Toxicol. 19:577–586. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zhou SF, Xue CC, Yu XQ and Wang G: Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab. 8:526–553. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ohno M, Darwish WS, Ikenaka Y, Miki W and Ishizuka M: Astaxanthin can alter CYP1A-dependent activities via two different mechanisms: induction of protein expression and inhibition of NADPH P450 reductase dependent electron transfer. Food Chem Toxicol. 49:285–1291. 2011. View Article : Google Scholar : PubMed/NCBI
12	Gradelet S, Astorg P, Pineau T, Canivenc MC, Siess MH, Leclerc J and Lesca P: Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and b-apo-8′-carotenal, with no affinity for the TCDD binding site. Biochem Pharmacol. 54:307–315. 1997.PubMed/NCBI
13	Breinholt V, Lauridsen ST, Daneshvar B and Jakobsen J: Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett. 154:201–210. 2000. View Article : Google Scholar : PubMed/NCBI
14	Astorg P, Gradelet S, Leclerc J and Siess MH: Effects of provitamin A or non-provitamin A carotenoids on liver xenobiotic-metabolizing enzymes in mice. Nutr Cancer. 27:245–249. 1997. View Article : Google Scholar : PubMed/NCBI
15	Liu CL, Lim YP and Hu ML: Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs. 10:242–257. 2012. View Article : Google Scholar
16	Firdous AP, Sindhu ER, Ramnath V and Kuttan R: Anti-mutagenic and anti-carcinogenic potential of the carotenoid meso-zeaxanthin. Asian Pac J Cancer Prev. 11:1795–1800. 2010.PubMed/NCBI
17	Wang H and Leung LK: The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition. 26:1181–1187. 2010.PubMed/NCBI
18	Gradelet S, Astorg P, Le Bon AM, Bergès R and Suschetet M: Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Cancer Lett. 114:221–223. 1997. View Article : Google Scholar : PubMed/NCBI
19	Kim KN, Ahn G, Heo SJ, Kang SM, Kang MC, Yang HM, Kim D, Roh SW, Kim SK, Jeon BT, Park PJ, Jung WK and Jeon YJ: Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol. 35:39–46. 2013. View Article : Google Scholar : PubMed/NCBI
20	Yu RX, Hu XM, Xu SQ, Jiang ZJ and Yang W: Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur J Pharmacol. 657:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Chen S, Xu S, Yu X, Ma D, Hu X and Cao X: In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drug. 10:2055–2068. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kim JM, Araki S, Kim DJ, Park CB, Takasuka N, Baba-Toriyama H, Ota T, Nir Z, Khachik F, Shimidzu N, Tanaka Y, Osawa T, Uraji T, Murakoshi M, Nishino H and Tsuda H: Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethyhydrazine initiation. Carcinogenesis. 19:81–85. 1998. View Article : Google Scholar : PubMed/NCBI
23	Okuzumi J, Takahashi T, Yamane T, Kitao Y, Inagake M, Ohya K, Nishino H and Tanaka Y: Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N′-nitro-N-nitrosoguanidine-induced mouse duodenal carcinogenesis. Cancer Lett. 68:159–168. 1993.PubMed/NCBI
24	Ciolino HP, MacDonald CJ and Yeh GC: Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Cancer Res. 62:3685–3690. 2002.PubMed/NCBI
25	Goralczyk R: Beta-carotene and lung cancer in smokers: review of hypotheses and status of research. Nutr Cancer. 61:767–774. 2009. View Article : Google Scholar : PubMed/NCBI